Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Efficacy and Safety of Dapagliflozin According to Frailty in Patients with Heart Failure: A Prespecified Analysis of the DELIVER Trial

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Mild-to-Moderate Kidney Dysfunction and Cardiovascular Disease: Observational and Mendelian Randomization Analyses

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Aptamer Proteomics for Biomarker Discovery in Heart Failure with Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Iron Deficiency in Heart Failure and Effect of Dapagliflozin: Findings From DAPA-HF

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Gender- and Age-Specific Rates of Heart Failure and other Adverse Cardiovascular Outcomes in Systemic Sclerosis

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Atrial Fibrillation and Dapagliflozin Efficacy in Patients With Preserved or Mildly Reduced Ejection Fraction

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Long-term risk of adverse cardiovascular outcomes associated with cutaneous lupus erythematosus: a nationwide cohort study

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Adherence and Discontinuation of Optimal Heart Failure Therapies According to Age: A Danish Nationwide Study

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Jawad H Butt
  • Pardeep S Jhund
  • Jan Belohlávek
  • Rudolf A de Boer
  • Chern-En Chiang
  • Akshai S Desai
  • Jaroslaw Drożdzż
  • Adrian F Hernandez
  • Silvio E Inzucchi
  • Tzvetana Katova
  • Masafumi Kitakaze
  • Mikhail N Kosiborod
  • Carolyn S P Lam
  • Anna Maria Langkilde
  • Daniel Lindholm
  • Erasmus Bachus
  • Felipe Martinez
  • Béla Merkely
  • Magnus Petersson
  • Jose F Kerr Saraiva
  • Sanjiv J Shah
  • Muthiah Vaduganathan
  • Orly Vardeny
  • Ulrica Wilderäng
  • Brian L Claggett
  • Scott D Solomon
  • John J V McMurray
View graph of relations

BACKGROUND: Frailty is increasing in prevalence. Because patients with frailty are often perceived to have a less favorable risk/benefit profile, they may be less likely to receive new pharmacologic treatments. We investigated the efficacy and tolerability of dapagliflozin according to frailty status in patients with heart failure with mildly reduced or preserved ejection fraction randomized in DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved Ejection Fraction Heart Failure).

METHODS: Frailty was measured using the Rockwood cumulative deficit approach. The primary end point was time to a first worsening heart failure event or cardiovascular death.

RESULTS: Of the 6263 patients randomized, a frailty index (FI) was calculable in 6258. In total, 2354 (37.6%) patients had class 1 frailty (FI ≤0.210; ie, not frail), 2413 (38.6%) had class 2 frailty (FI 0.211-0.310; ie, more frail), and 1491 (23.8%) had class 3 frailty (FI ≥0.311; ie, most frail). Greater frailty was associated with a higher rate of the primary end point (per 100 person-years): FI class 1, 6.3 (95% CI 5.7-7.1); class 2, 8.3 (7.5-9.1); and class 3, 13.4 (12.1-14.7; P<0.001). The effect of dapagliflozin (as a hazard ratio) on the primary end point from FI class 1 to 3 was 0.85 (95% CI, 0.68-1.06), 0.89 (0.74-1.08), and 0.74 (0.61-0.91), respectively (Pinteraction=0.40). Although patients with a greater degree of frailty had worse Kansas City Cardiomyopathy Questionnaire scores at baseline, their improvement with dapagliflozin was greater than it was in patients with less frailty: placebo-corrected improvement in Kansas City Cardiomyopathy Questionnaire Overall Summary Score at 4 months in FI class 1 was 0.3 (95% CI, -0.9 to 1.4); in class 2, 1.5 (0.3-2.7); and in class 3, 3.4 (1.7-5.1; Pinteraction=0.021). Adverse reactions and treatment discontinuation, although more frequent in patients with a greater degree of frailty, were not more common with dapagliflozin than with placebo irrespective of frailty class.

CONCLUSIONS: In DELIVER, frailty was common and associated with worse outcomes. The benefit of dapagliflozin was consistent across the range of frailty studied. The improvement in health-related quality of life with dapagliflozin occurred early and was greater in patients with a higher level of frailty.

REGISTRATION: URL: https://www.

CLINICALTRIALS: gov; Unique identifier: NCT03619213.

Original languageEnglish
JournalCirculation
Volume146
Issue number16
Pages (from-to)1210-1224
Number of pages15
ISSN0009-7322
DOIs
Publication statusPublished - 18 Oct 2022

    Research areas

  • Benzhydryl Compounds/adverse effects, Frailty/epidemiology, Glucosides/adverse effects, Heart Failure/drug therapy, Humans, Quality of Life, Stroke Volume, clinical trial, frailty, heart failure, dapagliflozin

ID: 80467072